Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations-Reference-Cited by-同舟云学术

Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations

Published:2012-11-16 Issue:23 Volume:55 Page:10685-10699
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Yang Jiao¹²,Wang Li-Jiao¹,Liu Jing-Jing¹,Zhong Lei¹,Zheng Ren-Lin¹,Xu Yong¹,Ji Pan¹,Zhang Chun-Hui¹,Wang Wen-Jing¹,Lin Xing-Dong¹,Li Lin-Li²,Wei Yu-Quan¹,Yang Sheng-Yong¹

Affiliation:

1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China

2. West China School of Pharmacy, Sichuan University, Sichuan 610041, China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm301365e

Reference32 articles.

1. Cancer statistics, 2012

2. First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations